Celcuity/$CELC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
- Ticker
- $CELC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 155
- Headquarters
- Minneapolis, United States
- Website
- www.celcuity.com
Celcuity Metrics
BasicAdvanced
$3.4B
-
-$4.32
0.20
-
Price and volume
Market cap
$3.4B
Beta
0.2
52-week high
$151.02
52-week low
$53.54
Average daily volume
1.6M
Financial strength
Current ratio
8.931
Quick ratio
8.68
Long term debt to equity
-59.004
Total debt to equity
-59.024
Interest coverage (TTM)
-9.37%
Profitability
EBITDA (TTM)
-208.479
Management effectiveness
Return on assets (TTM)
-25.78%
Return on equity (TTM)
-1,433.70%
Valuation
Price to book
-265.26
Price to tangible book (TTM)
-54
Price to free cash flow (TTM)
-18.885
Free cash flow yield (TTM)
-5.30%
Free cash flow per share (TTM)
-3.67
Growth
Earnings per share change (TTM)
25.32%
3-year earnings per share growth (CAGR)
18.29%
What the Analysts think about Celcuity
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Analyst projections of the future price of Celcuity stock.
Bulls say / Bears say
REVTORPYK is FDA-approved and commercially available in the US for eligible patients with PIK3CA wild-type advanced breast cancer. That gives Celcuity a route to product revenue rather than a thesis based only on future trial results. (U.S. Securities and Exchange Commission)
In the PIK3CA-mutant VIKTORIA-1 cohort, the triplet delivered median progression-free survival of 11.1 months versus 5.6 months with alpelisib plus fulvestrant. Celcuity has filed to expand the label to this group, which could broaden the drug’s eligible market if approved. (BioSpace)
Celcuity reported $754 million in cash, cash equivalents and short-term investments at the end of Q2 2026, and expects this to fund operations at least into 2029. That provides time to support the launch and advance its clinical programmes without an immediate need to raise more capital. (U.S. Securities and Exchange Commission)
The commercial launch began only on 30 September, so meaningful uptake is not yet demonstrated. Before launch, Celcuity used $55.4 million in operating cash in Q2 and reported a net loss of $78.9 million, creating pressure to turn the launch into sales. (U.S. Securities and Exchange Commission, U.S. Securities and Exchange Commission)
Celcuity raised $575 million through convertible senior notes. Conversion could dilute existing shareholders, while the notes also leave the company with a debt obligation. (U.S. Securities and Exchange Commission)
The approved product and the company’s principal clinical programmes all rely on gedatolisib. This concentrates the investment case in one drug: setbacks in safety, competition or execution could affect both current sales prospects and the wider pipeline. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
Celcuity Financial Performance
Revenues and expenses
Celcuity Earnings Performance
Company profitability
Upcoming events
No upcoming events
Celcuity News
AllArticlesVideos
Funds containing Celcuity
Fund name | Fund size | $CELC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.09% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.02% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.